Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inga Nehlmeier

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
The Lancet. Infectious Diseases|January 11, 2024
Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in GermanyAnne Cossmann, Markus Hoffmann, Metodi V Stankov, et al.
The Lancet. Infectious Diseases|September 28, 2024
Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccinationChristine Happle, Markus Hoffmann, Amy Kempf, et al.
Journal of Virology|June 26, 2015
Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and NeuraminidaseKerstin Gnirß, Pawel Zmora, Paulina Blazejewska, et al.
Journal of Virology|November 16, 2018
Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat CellsMarkus Hoffmann, Inga Nehlmeier, Constantin Brinkmann, et al.
Journal of the American Chemical Society|September 16, 2020
Glycan-Gold Nanoparticles as Multifunctional Probes for Multivalent Lectin-Carbohydrate Binding: Implications for Blocking Virus Infection and Nanoparticle AssemblyDarshita Budhadev, Emma Poole, Inga Nehlmeier, et al.
The Lancet. Infectious Diseases|November 3, 2022
The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineagesPrerna Arora, Lu Zhang, Inga Nehlmeier, et al.
Virology|August 10, 2012
The role of the alternative coreceptor GPR15 in SIV tropism for human cellsMiriam Kiene, Andrea Marzi, Andreas Urbanczyk, et al.
The Lancet. Infectious Diseases|November 15, 2025
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2Lu Zhang, Nianzhen Chen, Amy Eichmann, et al.
Cellular & Molecular Immunology|May 8, 2023
Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineageInga Nehlmeier, Amy Kempf, Prerna Arora, et al.
Journal of Virology|October 29, 2024
Acquisition of a multibasic cleavage site does not increase MERS-CoV entry into Calu-3 human lung cellsMarkus Hoffmann, Hannah Kleine-Weber, Luise Graichen, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
The Lancet. Infectious Diseases|January 11, 2024
Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in GermanyAnne Cossmann, Markus Hoffmann, Metodi V Stankov, et al.
The Lancet. Infectious Diseases|September 28, 2024
Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccinationChristine Happle, Markus Hoffmann, Amy Kempf, et al.
Journal of Virology|June 26, 2015
Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and NeuraminidaseKerstin Gnirß, Pawel Zmora, Paulina Blazejewska, et al.
Journal of Virology|November 16, 2018
Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat CellsMarkus Hoffmann, Inga Nehlmeier, Constantin Brinkmann, et al.
Journal of the American Chemical Society|September 16, 2020
Glycan-Gold Nanoparticles as Multifunctional Probes for Multivalent Lectin-Carbohydrate Binding: Implications for Blocking Virus Infection and Nanoparticle AssemblyDarshita Budhadev, Emma Poole, Inga Nehlmeier, et al.
The Lancet. Infectious Diseases|November 3, 2022
The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineagesPrerna Arora, Lu Zhang, Inga Nehlmeier, et al.
Virology|August 10, 2012
The role of the alternative coreceptor GPR15 in SIV tropism for human cellsMiriam Kiene, Andrea Marzi, Andreas Urbanczyk, et al.
The Lancet. Infectious Diseases|November 15, 2025
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2Lu Zhang, Nianzhen Chen, Amy Eichmann, et al.
Cellular & Molecular Immunology|May 8, 2023
Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineageInga Nehlmeier, Amy Kempf, Prerna Arora, et al.
Journal of Virology|October 29, 2024
Acquisition of a multibasic cleavage site does not increase MERS-CoV entry into Calu-3 human lung cellsMarkus Hoffmann, Hannah Kleine-Weber, Luise Graichen, et al.
Pageof 8